Anti-CTLA-4 immunotherapy mobilizes microglia against glioblastoma

Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) scientists has shown that a type of immunotherapy, called anti-CTLA-4, increases the survival of mice with glioblastoma. For a cancer that currently has no effective treatment options, this finding has sparked hope. Glioblastoma is the most common and aggressive form of brain cancer, and glioblastomas often spread throughout the brain, making surgical removal difficult. Therefore, investigating alternative therapies is essential.